Pionyr Immunotherapeutics to Present on Myeloid Tuning Platform and TREM1 Targeting Antibody Program at the Tumor Myeloid-Directed Therapies Summit
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Pionyr Immunotherapeutics, Inc., a company developing first-in-class Myeloid Tuning™ antibody therapeutics that enhance the body’s anti-tumor immunity by altering, or “tuning,” immune cells within the tumor microenvironment, announced that Chief Medical Officer Leonard Reyno, M.D., will lead a discussion on myeloid cell targeting to reprogram the...
